We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Merck said its oncology blockbuster Keytruda (pembrolizumab) is just as safe and effective in a dose of 400 mg every six weeks for first-line treatment of melanoma as at the approved dosing regimen of 200mg every three-weeks. Read More
Remdesivir should be part of the “first wave” of efforts to expedite COVID-19 treatments and vaccines, the members of Scientists to Stop COVID-19 said in a plan submitted to the White House. Read More
Challenge studies for COVID-19 vaccines are “incomprehensible” as long as there are safer alternatives, Generex CEO Joe Moscato said yesterday, responding to a letter from lawmakers last week on the subject. Read More
A New York healthcare network is studying famotidine, the active ingredient in the heartburn drug Pepcid, as a potential treatment for COVID-19. Read More
Vertex Pharmaceuticals’ cystic fibrosis drug Trikafta (elexacaftor/tezacaftor/ivacaftor) will need a dramatic price cut to be cost effective, the Institute for Clinical and Economic Review (ICER) found in a new analysis. Read More
Sanofi and Regeneron have modified their clinical trial of the rheumatoid arthritis drug Kevzara (sarilumab) as a COVID-19 treatment after preliminary results found no benefit in one group. Read More